Omics · study · 2026
Pre-clinical optimization of MDM2 antagonist treatment of glioblastoma
Listed in NCBI GEO
In glioblastomas wildtype p53 is inhibited by MDM2 or MDM4 amplification, or deletion of CDKN2A (coding for MDM2 inhibitor p14ARF).
Description
MDM2 pharmacological antagonists (MDM2a) are currently in clinical trials for wt p53 glioblastoma. Here we test the hypotheses that GBM response to MDM2a will vary, and that transcriptional activation signatures in response to MDM2a will have predictive value and support the identification of mechanisms of resistance.
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE291nnn/GSE291870 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291870 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1235692 ncbi.nlm.nih.gov/bioproject/PRJNA1235692 ↗
project · from NCBI GEO
Topics
- Stated by source
- Expression profiling by high throughput sequencing · Homo sapiens
- From keywords
- Life Sciences
Provenance · 1 source records, 7 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE291870 | 15 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencing | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[organism].NCBITaxon:9606 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |